April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Effects of Benzalkonium Chloride- or PolyquadTM-preserved Combination Glaucoma Medications on Human Trabecular Meshwork Cells
Author Affiliations & Notes
  • Malik Y. Kahook
    Ophthalmology, Univ of Colorado Denver, Aurora, Colorado
  • David A. Ammar
    Ophthalmology, Univ of Colorado Denver, Aurora, Colorado
  • Footnotes
    Commercial Relationships  Malik Y. Kahook, Alcon (F, C), Allergan (F, C), Genentech (F, C), Heidelberg Engineering (C), Ivantis (C), Merck (F, C), Pfizer (F), Vitreoretinal Technologies (C); David A. Ammar, Alcon (F)
  • Footnotes
    Support  Alcon
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4663. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Malik Y. Kahook, David A. Ammar; Effects of Benzalkonium Chloride- or PolyquadTM-preserved Combination Glaucoma Medications on Human Trabecular Meshwork Cells. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4663.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : We investigated the potential short and long-term effects in cultured human trabecular meshwork (TM) cells of various topical glaucoma formulations containing different preservatives.

Methods: : We tested the combination medication of 0.004% travoprost plus 0.5% timolol preserved with either 0.015% benzalkonium chloride (BAK) or with 0.001% polyquadTM (PQ); and 0.005% latanoprost plus 0.5% timolol preserved with 0.020% BAK. Also tested was a range of BAK concentrations (0.001 - 0.020%) in balanced salt solution (BSS). Controls included 100% Live (treated with BSS) and Dead (treated with 70% methanol). Cells were treated for 25 minutes at 37°C with solutions diluted 1:10 to mimic the reduced penetration of topical preparations to the anterior chamber. The percentage of live cells was determined immediately after treatment through the uptake of the fluorescent vital dye calcein-AM. To determine any long-term effects, we assayed release of matrix metalloproteinase 9 (MMP-9) 24 hours after treatments.

Results: : BAK solutions demonstrated a dose-dependent reduction in TM cell viability, ranging from 71 ± 5% live cells at 0.001% BAK (diluted 1:10) to 33 ± 3% live cells at 0.020% BAK (diluted 1:10). Travoprost with timolol preserved with BAK had statistically fewer live TM cells (79 ± 7%) than the same preparation preserved with PQ (93 ± 1%; p < 0.001). Latanoprost with timolol preserved with 0.020% BAK (29 ± 9% live cells) was similar to the 0.020% BAK treatment (33 ± 3%). However, travoprost with timolol preserved in 0.015% BAK had significantly more live cells (83 ± 12%) than the 0015% BAK (49 ±10%). We also found that 0.015% or 0.020% BAK treatment (diluted 1:100) resulted in elevated levels of extracellular MMP-9 at 24 hours.

Conclusions: : These results demonstrate that the substitution or removal of the preservative BAK from topical ophthalmic drugs results in greater viability of TM cells. Travoprost with timolol, but not latanoprost with timolol, countered some of the toxic BAK effects. BAK treatment appeared to cause release of elevated levels of MMP-9, a matrix metalloproteinase implicated in the pathogenesis of glaucoma.

Keywords: trabecular meshwork • cell survival • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.